Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy

Cancer

Volumn 116, Issue 16, 2010, Pages 3815-3824

  Goda, Jayant S ^a,b   Gospodarowicz, Mary ^a,b   Pintilie, Melania ^a,b   Wells, Woodrow ^a,b   Hodgson, David C ^a,b   Sun, Alexander ^a,b   Crump, Micheal ^a,b   Tsang, Richard W ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Extranodal; Long term outcome; Lymphomas; Mucosa associated lymphoid tissue (MALT); Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; ORBIT TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SALIVARY GLAND; SALIVARY GLAND CANCER; STOMACH; STOMACH LYMPHOMA; THYROID CANCER; THYROID GLAND; TREATMENT FAILURE; TREATMENT RESPONSE; COMPLICATION; DISEASE FREE SURVIVAL; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; SECOND CANCER; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77956792569     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25226     Document Type: Article

References (39)

1. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1984;53:2515-2524.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, eds. World Health Organization Classification of Tumours. 4th ed. Lyon, France: IARC Press; 2008:214-217.
3. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96:410-419.
4. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995;345:1591-1594.
5. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002;50(suppl 3):III19-III24.
6. Bertoni F, Conconi A, Capella C, et al. Molecular followup in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood. 2002;99:2541-2544.
7. Pariente D, Anaya JM, Combe B, et al. Non-Hodgkin's lymphoma associated with primary Sjogren's syndrome. Eur J Med. 1992;1:337-342.
8. Aozasa K. Hashimoto's thyroiditis as a risk factor of thyroid lymphoma. Acta Pathol Jpn. 1990;40:459-468.
9. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157-4164.
10. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4:161-168.
11. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84:1-12.
12. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
13. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed [published erratum appears in Blood 2000;95:2481]. Blood. 2000;95:802-806.
14. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624-1630.
15. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-2495. (Pubitemid 36857603)
16. Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematop. 2007;47:31-42.
17. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067-5073.
18. Ferreri AJ, Ponzoni M, Dognini GP, et al. Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. Ann Oncol. 2006;17:1721-1722. (Pubitemid 44680897)
19. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98:1375-1382. (Pubitemid 44530714)
20. Grunberger B, Hauff W, Lukas J, et al. 'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol. 2006;17:484-487.
21. Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys. 2003;57:172-176.
22. Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78:6-9.
23. Suh CO SS, Lee SW, Yang WI, Lee SY, Hahn JS. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys. 2006;65:228-233.
24. Du MQ, Peng HZ, Dogan A, et al. Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood. 1997;90:4071-4077.
25. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254-1258.
26. Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol. 2007;18:672-678.
27. Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong followup. Clin Cancer Res. 2005;11:3349-3352.
28. Yamashita H, Watanabe H, Ajioka Y, Nishikura K, Maruta K, Fujino MA. When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after helicobacter pylori eradication? Histopathology. 2000;37:131-140.
29. Papa A, Cammarota G, Tursi A, Gasbarrini A, Gasbarrini G. Helicobacter pylori eradication and remission of lowgrade gastric mucosa-associated lymphoid tissue lymphoma: a long-term follow-up study. J Clin Gastroenterol. 2000;31:169-171.
30. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916-1921.
31. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008;87:405-411.
32. Yamashita H, Nakagawa K, Asari T, Murakami N, Igaki H, Ohtomo K. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol. 2008;87:412-417.
33. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40.
34. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002;87:105-111.
35. Dabaja BS, Ha CS, Wilder RB, et al. Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J. 2003;9:321-324.
36. Raderer M, Chott A, Drach J, et al. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol. 2002;13:1094-1098.
37. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20:3872-3877.
38. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-2745.
39. Au WY, Gascoyne RD, Le N, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999;10:317-321.